PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

NCT04784767 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

FED

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
DRUG: Sodium chloride, USP, for injection (0.9% NaCl)
BIOLOGICAL: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

[object Object]
[object Object]